Abstract:p53‐knockout mice were more susceptible to radiation‐induced gastrointestinal (GI) toxicity and had a significantly shorter survival than p53‐wild‐type mice following radiation; however, antibiotics administration improved the survival and conferred protection against GI toxicity, thus linking p53 to the gut microbiome. Furthermore, p53‐knockout mice were also discovered to have a different gut microbiota profile compared with p53‐wild‐type mice. Two innate immunity‐related genes, Mbl2 and Lcn2, both having antimicrobial activity, were found directly transactivated by p53. This elucidates p53's involvement in shaping the gut microbiome through its downstream targets in the innate immune system and protecting the intestinal barrier. p53 is a key tumor suppressor mutated in half of human cancers. In recent years, p53 was shown to regulate a wide variety of functions. From the transcriptome analysis of 24 tissues of irradiated mice, we identified 553 genes markedly induced by p53. Gene Ontology (GO) enrichment analysis found that the most associated biological process was innate immunity. 16S rRNA‐seq analysis revealed that Akkermansia, which has anti‐inflammatory properties and is involved in the regulation of intestinal barrier integrity, was decreased in p53‐knockout (p53−/−) mice after radiation. p53−/− mice were susceptible to radiation‐induced GI toxicity and had a significantly shorter survival time than p53‐wild‐type (p53+/+) mice following radiation. However, administration of antibiotics resulted in a significant improvement in survival and protection against GI toxicity. Mbl2 and Lcn2, which have antimicrobial activity, were identified to be directly transactivated by p53 and secreted by liver into the circulatory system. We also found the expression of MBL2 and LCN2 was decreased in liver cancer tissues with p53 mutations compared with those without p53 mutations. These results indicate that p53 is involved in shaping the gut microbiome through its downstream targets related to the innate immune system, thus protecting the intestinal barrier.

Regulation of the innate immune response and gut microbiome by p53

p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome

p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis

P53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors.

Protective Effects of p53 Regulatory Agents Against High-LET Radiation-Induced Injury in Mice

p53 promotes revival stem cells in the regenerating intestine after severe radiation injury

p53 dynamics vary between tissues and are linked with radiation sensitivity

Functional Diversity of P53 in Human and Wild Animals

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

p53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice

DNA repair processes are critical mediators of p53-dependent tumor suppression

Quantitative Proteomics Analysis of the Effects of Ionizing Radiation in Wild Type and P53k317r Knock-in Mouse Thymocytes

REGγ mitigates radiation-induced enteritis by preserving mucin secretion and sustaining microbiome homeostasis

p53 Regulates Nuclear Architecture to Reduce Carcinogen Sensitivity and Mutagenic Potential

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

BAC transgenic mice provide evidence that p53 expression is highly regulated in vivo

Fine-tuning P53 Activity Through C-terminal Modification Significantly Contributes to HSC Homeostasis and Mouse Radiosensitivity.

Chemotherapy mediates intestinal injury via p53/p53 upregulated modulator of apoptosis (PUMA) signaling pathway

Mutant p53 leads to low-grade IFN-I-induced inflammation and impairs cGAS-STING signalling in mice

Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers